BTK and Schwartz-Jampel syndrome: Based on our current findings, together with the observed increase in BTK protein expression levels in circulating B cells from patients with RA and SjS (15), it is attractive to speculate that Btk inhibition will dampen both BCR pathway activation and synergistic BCR/TLR signaling in patients with systemic autoimmune disease.